ADAMTS13 and Decreased liver function: Surprisingly, ADAMTS13-Act was not related to VWF biomarkers or the VWF-Ag/-A ratio, and also similar between different stages of PH and liver dysfunction in our cohort of clinically stable ACLD patients and liver-healthy controls, which add important data to the controversy on ADAMTS13-Act in ACLD.